Alison Moore's most recent trade in Codexis Inc. was a trade of 500,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Codexis Inc | Alison Moore | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc | Alison Moore | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 85,000 | 254,332 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 2.51 per share. | 13 Oct 2025 | 6,239 | 169,332 (0%) | 0% | 2.5 | 15,629 | Common Stock |
| Artiva Biotherapeutics Inc | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 13,750 | 13,750 | - | - | Director Stock Option (Right to Buy) | |
| Codexis Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 161,250 | 161,250 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 26,875 | 175,571 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 50,000 | 148,696 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 30,120 | 98,696 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 34,602 | 68,576 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 558,094 | 672,731 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 432,738 | 432,738 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 14 Mar 2023 | 8,351 | 114,637 (0%) | 0% | 5.5 | 45,990 | Common Stock |
| Codexis Inc | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 11,273 | 33,974 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 737,179 | 737,179 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 15 Mar 2022 | 8,698 | 120,430 (0%) | 0% | 7.6 | 66,388 | Common Stock |
| Codexis Inc | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,796 | 22,701 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 92,365 | 92,365 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 24,866 | 127,440 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 15 Mar 2021 | 6,164 | 102,574 (0%) | 0% | 38.1 | 235,089 | Common Stock |